1. Field of the Invention
The present invention relates generally to a device and method for attaching to bones.
2. Description of Related Art
Broken bones, such as compression fractures of one or more vertebrae in the spine, may be treated with internal fixation. Any indication needed spinal stability can also be treated by internal fixation. Examples include scoliosis, kyphosis, spondylothisthesis and rotation, segmental instability, such as disc degeneration and fracture caused by disease and trauma and congenital defects, and degeneration caused by tumors.
As shown by
Backing out or loosening of the fixation screws can cause a reduction of the fixation, up to complete failure or even resulting in additional complications.
Furthermore, the bones are often weak and under heavy loads, the bones can fail and the fixation screws can be ripped from the bone resulting in complete failure and additional damage to the bone.
Therefore, a fixation screw that can substantially eliminate the risk of backout, and can provide a higher anchoring force is desired. A fixation screw that can also minimize bone failure is desired.
An expandable attachment device and methods for using the same are disclosed. The expandable attachment device can have a radially expandable section and a distal end. The distal end can be configured to be attached to a separate device, such as a fixation rod or plate. The device can have an unexpandable section.
Also disclosed is an expandable attachment device that can have a radially expandable section and an unexpandable section. The unexpandable section and/or the radially expandable section can have external threads.
The devices described herein can be used as substitutes for fixation screws in existing fixation systems. The devices can be used to treat broken bones, scoliosis, kyphosis, spondylothisthesis and rotation, segmental instability, such as disc degeneration and fracture caused by disease and trauma and congenital defects, and degeneration caused by tumors.
The devices can be configured to be used in systems with fixed screw longitudinal axis or polyaxial configurations.
a through
a through 30d illustrate cross-section X-X of
a through 31d illustrate cross-section X-X of
The expandable attachment device 2 can have an expandable attachment device axis 10. The expandable device axis can be substantially straight.
The proximal end of the expandable attachment device 2 can have a tip 12. The tip 12 can be sharpened or otherwise configured to seat the expandable attachment device 2 in bone (e.g., having cutting teeth). The unexpandable section 4 can have unexpandable thread 14, for example, configured to screw the expandable attachment device 2 into bone.
The expandable section 6 can be resiliently and/or deformably expandable. The expandable sections 6 can be radially expanded by axial compression (e.g., see
The expandable attachment device 2 can be substantially flat or planar.
The expandable section 6 can be biased to resiliently radially expand. For example, the expandable section 6 can be self-expandable or releasable spring. The expandable section 6 can be resiliently radially expandable and can be additionally deformably radially expandable to a larger radius than achieved by resilient expansion alone.
The expandable section 6 can have one or more anchors extending radially therefrom when the expandable section 6 is in the radially expanded configuration. The anchors can be brads, hooks, pins, teeth, fasteners, pegs, screws, skewers, spikes, stakes, or combinations thereof.
The expandable attachment device 2 can be configured to radially expand in volumetrically, for example to have radial expansion in two dimensions. The expandable attachment device 2 can be configured to radially expand planarly, for example, in a single dimension (i.e., to have radial expansion in only two substantially opposite directions).
When the expandable attachment device 2 is inserted in a bone, such as a vertebra, the expandable attachment device 2 can follow a longitudinal axis of insertion that is straight, curved, or a combination thereof. For example, the expandable attachment device 2 can follow a longitudinal axis of insertion through the bone that is substantially similar in shape to the expandable attachment device axis 10.
The deployment tool 16 (or expandable attachment device 2) can have a deployment rod 44, for example to transmit the compressive force to the deployment cap 42. The deployment rod 44 can be releasably attached to the deployment cap 42, for example via a releasable deployment anchor 46. The releasable deployment anchor 46 can be released and the deployment rod 44 can be removed after the expandable section 6 is radially expanded.
The cells 50 can be W-shaped, A-shaped, V-shaped, another configuration disclosed herein for cells 40, or combinations thereof. A single expandable section can have various cell 40 configurations.
A scale 51 is shown numbered in millimeters.
The longitudinally distal end 8 can be removably or fixedly attached to a cap. The cap can be configured to attach to the fixation joint 48.
A scale 51 is shown numbered in millimeters.
a-e illustrate variations of the strut 26, port 30 and joint 28 configuration of the expandable section.
The expandable attachment device 2 can have an engagement configuration, such as thread 33, that can be configured to removably attach to a deployment tool. The engagement configuration can be at or near the proximal end of the expandable support device 2. The engagement configuration can have a tool port 35. The tool port 35 can be configured to engage a deployment tool, for example a hex key or Allen wrench. The tool port 35 can be an open port. The tool port 35 can provide access through the proximal end of the expandable support device into the central channel 37 of the expandable support device. For example, filler can be deployed through the tool port 35 and into the central channel 37. Filler can then exit from the central channel 37 through the cells or side ports 30 and, for example, into the cancellous bone surrounding the device 2.
b illustrates that the struts 26 and ports 30 can be substantially identical along the entire length of the expandable section 6.
The tool handles can be configured to ratchet (i.e., unidirectional movement or substantially free unidirectional motion with safety-controlled bidirectional motion). The tool handles can be configured to control rotation and translation or screwing of the expandable attachment device 2 into the target site. The tool handles can be configured to control the expandable attachment device 2 attachment to and release from the deployment tool 16. The tool handles can be configured to control the radial expansion 38 of the expandable attachment device 2.
The tool handles can be longitudinally translatable and/or rotatable. The tool handles can be configured for ergonomic use. The third tool handle 66 can have a knurled surface. The second tool handle 64 can have wings, for example configured as finger or thumb controls. The first tool handle 62 can have a configuration that is conical, cylindrical or combinations thereof.
The deployment tool 16 can have a tool shaft 74. The expandable attachment device 2 can be releasably attached to the tool shaft 74.
a illustrates that the tool shaft 74 can have an expander driver 72 and a screw driver 70. The terminal end of the tool shaft 74 can be aligned with the distal end 8 of the expandable attachment device 2.
b illustrates that the terminal end of the tool shaft 74 can be placed, as shown by arrow, in contact with the expandable attachment device 2. The screw driver 70 (e.g., the distal end of the deployment tool attachment) can releasably attach to or engage the distal end 8. The expander driver 72 can releasably attach to or engage the expander head (e.g., the expander deployment tool attachment). The deployment tool 16 can screw the expandable attachment device 2 into a target tissue site (e.g., a bone, such as vertebral body 76).
c illustrates that the expander driver 72 can deploy a longitudinal compressive force, shown by arrow 36, to the expander 52. The surrounding tissue can resist the longitudinal compressive force, as shown by in vivo resisting force arrow 78. The expander 52 fingers can radially expand, as shown by arrows 38. The expander 52 fingers can force the expandable section 6 (e.g., the struts 26) radially outward, as shown by arrows. The expandable attachment device 2 can be deformably or resiliently radially expanded.
d illustrates that the tool shaft 74 can be detached or disengaged and withdrawn from the expandable attachment device 2 and the target site.
a illustrates that the tool shaft 74 can have a holder shaft 82 terminating in one or more holder grips 86. The holder grips 86 can be rotatably attached to the holder shaft 82 at holder hinges. When the tool shaft 74 is aligned with and adjacent to the expandable attachment device 2, the holder grips 86 can be flexed or rotated radially outward. The holder grips 86 can be configured to attach to the distal end 8 of the expandable attachment device 2.
b illustrates that the terminal end of the tool shaft 74 call be placed, as shown by arrow, in contact with the expandable attachment device 2. When the tool shaft 74 is attached to or engaged with the expandable attachment device 2, the holder grips 86 can be flexed or rotated radially inward. The holder grips 86 can attach to the distal end 8 of the expandable attachment device 2.
c illustrates that the expander driver 72 can deploy a longitudinal compressive force 36, shown by arrow, to the expander 52. The surrounding tissue can resist the longitudinal compressive force 36, as shown by in vivo resisting force arrow 78, and/or the holder shaft 82 and holder grips 86 can pull, as shown by arrows 84, on the distal end 8 producing an external resisting force to oppose the longitudinal compressive force, as shown by arrow 36.
The expander 52 fingers can radially expand, as shown by arrows 38. The expander 52 fingers can force the expandable section 6 (e.g., the struts 26) radially outward, as shown by arrows. The expandable attachment device 2 can be deformably or resiliently radially expanded.
d illustrates that the holder grips 86 can flex or rotate radially outward, as shown by arrows. The holder grips 86 can detach or disengage from the distal end 8 of the expandable attachment device 2. The tool shaft 74 can be withdrawn from the expandable attachment device 2 and the target site.
The expandable attachment device 2 can be removed by reversing the deployment method. For example, the expander 52 and/or screw can be longitudinally pulled and expanded resulting in radial contraction of the expandable attachment device 2 (e.g., the struts 26). The expandable attachment device 2 can then be unscrewed or otherwise removed from the target site.
The distal end 8 can extend from the bone. A separate device, such as a fixation rod 94 or plate, can be attached to the distal end 8.
The fixation joint 48 can rotate, as shown by arrow 45, relative to the remainder of the expandable attachment device 2.
During the application of the longitudinal force, the unexpandable section 4 of the expandable attachment device 2 can remain substantially stationary, for example, due to normal resistive forces from the surrounding tissue in vivo, and/or due to external resistive forces 84 deployed by the deployment tool 16, for example on the distal end 8 of the expandable attachment device 2 (e.g., as shown in
The cells on the first expandable attachment device 2a can be obstructed (i.e., be out of phase or out of sequence) by the struts 26 of the second expandable attachment device 2b, and/or the cells 50 on the first expandable attachment device 2b can be open and align (i.e., be in phase or in sequence) with the cells 50 of the second expandable attachment device 2b. Filler can be introduced into the second expandable attachment device 2b and deployed through the cells 50 of the first and second expandable attachment devices 2b into the target site.
Any or all elements of the expandable attachment device 2 and/or other devices or apparatuses described herein can be made from, for example, a single or multiple stainless steel alloys, nickel titanium alloys (e.g., Nitinol), cobalt-chrome alloys (e.g., ELGILOY® from Elgin Specialty Metals, Elgin, Ill.; CONICHROME® from Carpenter Metals Corp., Wyomissing, Pa.), nickel-cobalt alloys (e.g., MP35N® from Magellan Industrial Trading Company, Inc., Westport, Conn.), molybdenum alloys (e.g., molybdenum TZM alloy, for example as disclosed in International Pub. No. WO 03/082363 A2, published 9 Oct. 2003, which is herein incorporated by reference in its entirety), tungsten-rhenium alloys, for example, as disclosed in International Pub. No. WO 03/082363, polymers such as polyethylene teraphathalate (PET), polyester (e.g., DACRON® from E. I. Du Pont de Nemours and Company, Wilmington, Del.), poly ester amide (PEA), polypropylene, aromatic polyesters, such as liquid crystal polymers (e.g., Vectran, from Kuraray Co., Ltd., Tokyo, Japan), ultra high molecular weight polyethylene (i.e., extended chain, high-modulus or high-performance polyethylene) fiber and/or yarn (e.g., SPECTRA® Fiber and SPECTRA® Guard, from Honeywell International, Inc., Morris Township, N.J., or DYNEEMA® from Royal DSM N.V., Heerlen, the Netherlands), polytetrafluoroethylene (PTFE), expanded PTFE (ePTFE), polyether ketone (PEK), polyether ether ketone (PEEK), poly ether ketone ketone (PEKK) (also poly aryl ether ketone ketone), nylon, polyether-block co-polyamide polymers (e.g., PEBAX® from ATOFINA, Paris, France), aliphatic polyether polyurethanes (e.g., TECOFLEX® from Thermedics Polymer Products, Wilmington, Mass.), polyvinyl chloride (PVC), polyurethane, thermoplastic, fluorinated ethylene propylene (FEP), absorbable or resorbable polymers such as polyglycolic acid (PGA), poly-L-glycolic acid (PLGA), polylactic acid (PLA), poly-L-lactic acid (PLLA), polycaprolactone (PCL), polyethyl acrylate (PEA), polydioxanone (PDS), and pseudo-polyamino tyrosine-based acids, extruded collagen, silicone, zinc, echogenic, radioactive, radiopaque materials, a biomaterial (e.g., cadaver tissue, collagen, allograft, autograft, xenograft, bone cement, morselized bone, osteogenic powder, beads of bone) any of the other materials listed herein or combinations thereof. Examples of radiopaque materials are barium sulfate, zinc oxide, titanium, stainless steel, nickel-titanium alloys, tantalum and gold.
Any or all elements of the expandable attachment device 2 and/or other devices or apparatuses described herein, can be, have, and/or be completely or partially coated with agents for cell ingrowth.
The expandable attachment device 2 and/or elements of the expandable attachment device 2 and/or other devices or apparatuses described herein can be filled, coated, layered and/or otherwise made with and/or from cements, fillers, and/or glues known to one having ordinary skill in the art and/or a therapeutic and/or diagnostic agent. Any of these cements and/or fillers and/or glues can be osteogenic and osteoinductive growth factors.
Examples of such cements and/or fillers includes bone chips, demineralized bone matrix (DBM), calcium sulfate, coralline hydroxyapatite, biocoral, tricalcium phosphate, calcium phosphate, polymethyl methacrylate (PMMA), biodegradable ceramics, bioactive glasses, hyaluronic acid, lactoferrin, bone morphogenic proteins (BMPs) such as recombinant human bone morphogenetic proteins (rhBMPs), other materials described herein, or combinations thereof.
The agents within these matrices can include any agent disclosed herein or combinations thereof, including radioactive materials; radiopaque materials; cytogenic agents; cytotoxic agents; cytostatic agents; thrombogenic agents, for example polyurethane, cellulose acetate polymer mixed with bismuth trioxide, and ethylene vinyl alcohol; lubricious, hydrophilic materials; phosphor cholene; anti-inflammatory agents, for example non-steroidal anti-inflammatories (NSAIDs) such as cyclooxygenase-1 (COX-1) inhibitors (e.g., acetylsalicylic acid, for example ASPIRIN® from Bayer AG, Leverkusen, Germany; ibuprofen, for example ADVIL® from Wyeth, Collegeville, Pa.; indomethacin; mefenamic acid), COX-2 inhibitors (e.g., VIOXX® from Merck & Co., Inc., Whitehouse Station, N.J.; CELEBREX® from Pharmacia Corp., Peapack, N.J.; COX-1 inhibitors); immunosuppressive agents, for example Sirolimus (RAPAMUNE®, from Wyeth, Collegeville, Pa.), or matrix metalloproteinase (MMP) inhibitors (e.g., tetracycline and tetracycline derivatives) that act early within the pathways of an inflammatory response. Examples of other agents are provided in Walton et al, Inhibition of Prostoglandin E2 Synthesis in Abdominal Aortic Aneurysms, Circulation, Jul. 6, 1999, 48-54; Tambiah et al, Provocation of Experimental Aortic Inflammation Mediators and Chlamydia Pneumoniae, Brit. J Surgery 88 (7), 935-940; Franklin et al, Uptake of Tetracycline by Aortic Aneurysm Wall and Its Effect on Inflammation and Proteolysis, Brit. J Surgery 86 (6), 771-775; Xu et al, Spl Increases Expression of Cyclooxygenase-2 in Hypoxic Vascular Endothelium, J. Biological Chemistry 275 (32) 24583-24589; and Pyo et al, Targeted Gene Disruption of Matrix Metalloproteinase-9 (Gelatinase B) Suppresses Development of Experimental Abdominal Aortic Aneurysms, J. Clinical Investigation 105 (11), 1641-1649 which are all incorporated by reference in their entireties.
Other examples of fractures types that can be treated with the disclosed device and method include Greenstick fractures, transverse fractures, fractures across growth plates, simple fractures, wedge fractures, complex fractures, compound fractures, complete fractures, incomplete fractures, linear fractures, spiral fractures, transverse fractures, oblique fractures, comminuted fractures, impacted fractures, and soft tissue tears, separations (e.g., avulsion fracture), sprains, and combinations thereof. Plastic deformations of bones can also be treated with the disclosed device and method.
Other examples of bones that can be treated with the disclosed device and method include the fingers (e.g., phalanges), hands (e.g., metacarpals, carpus), toes (e.g., tarsals), feet (metatarsals, tarsus), legs (e.g., femur, tibia, fibula), arms (e.g., humerus, radius, ulna), scapula, coccyx, pelvis, clavicle, scapula, patella, sternum, ribs, or combinations thereof.
Devices, elements and configurations disclosed as expandable support devices in the following applications can be used for the expandable section 6 in the present application, and the following applications are incorporated by reference herein in their entireties: PCT Application No. 2005/034115 filed Sep. 21, 2005, PCT Application No. 2006/016553 filed Apr. 27, 2006, PCT Application No. 2005/034742 filed Sep. 26, 2005, PCT Application No. 2005/034728 filed Sep. 26, 2005, PCT Application No. 2005/037126 filed Oct. 12, 2005, PCT Application No. 2006/062333 filed Dec. 19, 2006, PCT Application No. 2006/038920 filed Oct. 4, 2006, PCT Application No. 2006/027601 filed Jul. 14, 2006, PCT Application No. 2006/062201 filed Dec. 15, 2006, PCT Application No. 2006/062339 filed Dec. 19, 2006, PCT Application No. 2006/048667 filed Dec. 19, 2006, and U.S. patent application Ser. No. 11/457,772 filed Jul. 14, 2006.
All dimensions shown herein are exemplary. The dimensions shown herein can at least be expanded to ranges from about 50% to about 150% of the exemplary dimension shown herein, more narrowly from about 75% to about 125% of the exemplary dimension shown herein.
The use of the term “radial expansion” herein refers to both a volumetric increase of an element, or an increase in the radial dimension of the element itself, or the increase in the maximum radius of the element as measured from the expandable attachment device axis 10.
Any elements described herein as singular can be pluralized (i.e., anything described as “one” can be more than one). Any species element of a genus element can have the characteristics or elements of any other species element of that genus. The above-described configurations, elements or complete assemblies and methods and their elements for carrying out the invention, and variations of aspects of the invention can be combined and modified with each other in any combination.
This application claims the benefit of U.S. Provisional Application No. 60/985,087, filed Nov. 2, 2007, which is incorporated by reference herein in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
1438648 | Jacobs | Dec 1922 | A |
4738255 | Goble et al. | Apr 1988 | A |
5037422 | Hayhurst et al. | Aug 1991 | A |
5046513 | Gatturna et al. | Sep 1991 | A |
5065490 | Wivagg et al. | Nov 1991 | A |
5207679 | Li | May 1993 | A |
5209753 | Biedermann et al. | May 1993 | A |
5236445 | Hayhurst et al. | Aug 1993 | A |
5261909 | Sutterlin et al. | Nov 1993 | A |
5360431 | Puno et al. | Nov 1994 | A |
5411522 | Trott | May 1995 | A |
5472452 | Trott | Dec 1995 | A |
5474555 | Puno et al. | Dec 1995 | A |
5480403 | Lee et al. | Jan 1996 | A |
5489210 | Hanosh | Feb 1996 | A |
5501695 | Anspach, Jr. et al. | Mar 1996 | A |
5522844 | Johnson | Jun 1996 | A |
5643321 | McDevitt | Jul 1997 | A |
5649950 | Bourne et al. | Jul 1997 | A |
5662654 | Thompson | Sep 1997 | A |
5709708 | Thal | Jan 1998 | A |
5749899 | Bardin | May 1998 | A |
5782866 | Wenstrom, Jr. | Jul 1998 | A |
5797963 | McDevitt | Aug 1998 | A |
5824011 | Stone et al. | Oct 1998 | A |
5849004 | Bramlet | Dec 1998 | A |
5882350 | Ralph et al. | Mar 1999 | A |
5935129 | McDevitt et al. | Aug 1999 | A |
6146406 | Shluzas et al. | Nov 2000 | A |
6168597 | Biedermann et al. | Jan 2001 | B1 |
6200330 | Benderev et al. | Mar 2001 | B1 |
6224604 | Suddaby | May 2001 | B1 |
6319255 | Grundei et al. | Nov 2001 | B1 |
6458100 | Roue et al. | Oct 2002 | B2 |
6506051 | Levisman | Jan 2003 | B2 |
6585770 | White et al. | Jul 2003 | B1 |
6648893 | Dudasik | Nov 2003 | B2 |
6652561 | Tran | Nov 2003 | B1 |
7097648 | Globerman et al. | Aug 2006 | B1 |
20020049447 | Li | Apr 2002 | A1 |
20020165544 | Perren et al. | Nov 2002 | A1 |
20040138707 | Greenhalgh | Jul 2004 | A1 |
20050065526 | Drew et al. | Mar 2005 | A1 |
20050143827 | Globerman et al. | Jun 2005 | A1 |
20050187555 | Biedermann et al. | Aug 2005 | A1 |
20050228391 | Levy et al. | Oct 2005 | A1 |
20060015104 | Dalton | Jan 2006 | A1 |
20060052788 | Thelen et al. | Mar 2006 | A1 |
20060084987 | Kim | Apr 2006 | A1 |
20060190090 | Plaskon | Aug 2006 | A1 |
20060224241 | Butler et al. | Oct 2006 | A1 |
20060235391 | Sutterlin | Oct 2006 | A1 |
20060264950 | Nelson et al. | Nov 2006 | A1 |
20060271061 | Beyar et al. | Nov 2006 | A1 |
20070032791 | Greenhalgh | Feb 2007 | A1 |
20070093899 | Dutoit et al. | Apr 2007 | A1 |
20070198018 | Biedermann et al. | Aug 2007 | A1 |
20070282443 | Globerman et al. | Dec 2007 | A1 |
20080288003 | McKinley | Nov 2008 | A1 |
Number | Date | Country |
---|---|---|
0129442 | Dec 1984 | EP |
0574707 | Dec 1993 | EP |
4-502567 | May 1992 | JP |
11-504550 | Apr 1999 | JP |
2002-514935 | May 2002 | JP |
WO 9525469 | Sep 1995 | WO |
WO 0044319 | Aug 2000 | WO |
WO 0044321 | Aug 2000 | WO |
WO 0044946 | Aug 2000 | WO |
WO 0154598 | Aug 2001 | WO |
WO 03003951 | Jan 2003 | WO |
WO 03047440 | Jun 2003 | WO |
WO 2005034764 | Apr 2005 | WO |
WO 2005096975 | Oct 2005 | WO |
WO 2006034396 | Mar 2006 | WO |
WO 2006034436 | Mar 2006 | WO |
WO 2006037013 | Apr 2006 | WO |
WO 2006068682 | Jun 2006 | WO |
WO 2006116760 | Nov 2006 | WO |
WO 2006116761 | Nov 2006 | WO |
WO 2006126979 | Nov 2006 | WO |
WO 2007041665 | Apr 2007 | WO |
WO 2007065137 | Jun 2007 | WO |
WO 2007076374 | Jul 2007 | WO |
WO 2007076377 | Jul 2007 | WO |
Entry |
---|
Franklin, I.J. et al., “Uptake of Tetracycline by Aortic Aneurysm Wall and Its Effect on Inflammation and Proteolysis,” Brit J. Surger, 86(6):771-775, 1999. |
Pyo, R. et al., “Targeted Gene Disruption of Matrix Metalloproteinase-9 (Gelatinase B) Suppresses Development of Experimental Abdominal Aortic Aneurysms,” J. Clinical Investigation, 105(11):1641-1649, Jun. 2000. |
Tambiah, J. et al., “Provocation of Experimental Aortic Inflammation Mediators and Chlamydia Pneumoniae,” Brit., J. Surgery, 88(7):935-940, Feb. 2001. |
Walton, L.J. et al., “Inhibition of Prostoglandin E2 Synthesis in Abdominal Aortic Aneurysms,” Circulation, 48-54, Jul. 6, 1999. |
Xu, Q. et al., “Sp1 Increases Expression of Cyclooxygenase-2 in Hypoxic Vascular Endothelium,” J. Biological Chemistry, 275(32):24583-24589, Aug. 2000. |
Number | Date | Country | |
---|---|---|---|
20090131992 A1 | May 2009 | US |
Number | Date | Country | |
---|---|---|---|
60985087 | Nov 2007 | US |